Saturday, July 11, 2026

pharma · Pulmonary Embolism · Carcinoma, Hepatocellular

Bayer HealthCare Animal

Bayer HealthCare AG is a pharma organization headquartered in EU. Primary therapeutic focus areas include Pulmonary Embolism, Carcinoma, Hepatocellular, Colorectal Neoplasms, Macular Edema, Prevention of Ischemic Stroke.

3915 S 48TH STREET TER, St. Joseph, Missouri 64503, us HQ
1919 Founded
8 Employees
EMA registrant Type
Company details
Status
Public
HQ
3915 S 48TH STREET TER, St. Joseph, Missouri 64503, us
Founded
1919
Employees
8
Programs
34
Drugs
32
Patents
24
Clinical program

Ciprofloxacin (Cipro InhaIe, BAYQ3939)

Phase 1 · small molecule · Pulmonary Disease, Chronic Obstructive

Ciprofloxacin (Cipro InhaIe, BAYQ3939) for Pulmonary Disease, Chronic Obstructive is a Phase 1 program (small_molecule) at Bayer HealthCare AG with 1 ClinicalTrials.gov record(s).

← All Bayer HealthCare AG projects Phase 1 small molecule completed

Internal code 14019

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Bayer HealthCare AG
Phase
Phase 1
Modality
small_molecule
Indication
Pulmonary Disease, Chronic Obstructive
Status
completed
Trials
1